B cell

$28.8 Billion Worldwide Cell Analysis Industry to 2027 - Featuring Agilent Technologies, BD Biosciences, Danaher and Illumina Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022

Cell analysis refers to an umbrella term for a wide variety of technologies that are utilized to study genetic and phenotypical characteristics of a cell.

Key Points: 
  • Cell analysis refers to an umbrella term for a wide variety of technologies that are utilized to study genetic and phenotypical characteristics of a cell.
  • Cell analysis is typically done to understand population heterogeneity, identifying minority sub-populations of interest, as well as discovering unique characteristics of individual cells.
  • Cell analysis is utilized across academic and research laboratories, hospitals, and biotechnology and pharmaceutical, for studying stem cells, immunology, neurology, non-invasive prenatal diagnosis and in-vitro fertilization.
  • What is the structure of the global cell analysis market and who are the key players?

Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027

Retrieved on: 
Thursday, September 29, 2022

Overall, proenzymes appeared to exert significant effects against more aggressive, less differentiated tumor types, like pancreatic and ovarian tumors.

Key Points: 
  • Overall, proenzymes appeared to exert significant effects against more aggressive, less differentiated tumor types, like pancreatic and ovarian tumors.
  • Patients from the compassionate use study suffering from cancers of the GI tract, or endocrine tumors, such as pancreatic and ovarian cancers, benefited most from treatment.
  • In addition, assays revealed that the migration capacity of ovarian, pancreatic, melanoma and colon cancer cells was suppressed after incubation with PRP.
  • In the case of pancreatic and ovarian cancers, 2 from 4 pancreatic cancer patients and 4 from 7 ovarian cancer patients significantly exceeded life expectancy.

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

Retrieved on: 
Thursday, September 29, 2022

These data reinforce our commitment to advance transformational cell therapy research and underscore the potential of our NAM technology platform.

Key Points: 
  • These data reinforce our commitment to advance transformational cell therapy research and underscore the potential of our NAM technology platform.
  • The long-term, durable clinical benefit of omidubicel was observed at three years across a patient population that typically has a poor prognosis.
  • Learn More
    Overall well-being health-related quality of life scores for patients treated with omidubicel demonstrated clinical benefit compared to standard of care.
  • These data suggest clinically meaningful and sustained improvements in physical, functional, and overall well-being compared to umbilical cord blood transplantation.

Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody

Retrieved on: 
Wednesday, September 28, 2022

Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for immuno-fibrotic diseases and oncology, today announced the initiation of dosing in a Phase 1 study of LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody.

Key Points: 
  • Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for immuno-fibrotic diseases and oncology, today announced the initiation of dosing in a Phase 1 study of LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody.
  • The Phase 1 single and multiple ascending dose study will evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of LASN01 in healthy volunteers.
  • The initiation of this Phase 1 trial and the LASN01 clinical program is based in part on pre-clinical data reported at the American Thoracic Society (ATS) Annual Meeting 2022.
  • Inhibition of IL-11 signaling also showed a significant anti-fibrotic effect in the lung and skin in animal models of fibrosis.

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking e-Posters at the 51st Annual European Society for Dermatological Research Meeting

Retrieved on: 
Wednesday, September 28, 2022

The new translational data presented at ESDR provide novel and differentiated mechanistic insights into IL-13R1 mediated cytokine signaling in AD.

Key Points: 
  • The new translational data presented at ESDR provide novel and differentiated mechanistic insights into IL-13R1 mediated cytokine signaling in AD.
  • These data support the importance of IL-13R1 as a target in AD, providing a potentially differentiated approach for eblasakimab to reduce inflammation and itch in AD patients.
  • Data presented in this poster confirm prior results of eblasakimab dampening neuronal sensitization caused by IL-4 and IL-13 on human neurons.
  • 001- 38475), including the Companys Annual Report on Form 20-F filed with the US Securities and Exchange Commission on March 25, 2022.

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

Retrieved on: 
Wednesday, September 28, 2022

Wyndham Grand Hotel in Jupiter, Florida

Key Points: 
  • Wyndham Grand Hotel in Jupiter, Florida
    Please contact your Dawson James Security representative to schedule one-on-one meetings with the management team during the conference.
  • BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.
  • We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure.
  • The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Retrieved on: 
Wednesday, September 28, 2022

LEIDEN, The Netherlands, Sept. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older in the US. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023, aligned with a Priority Review classification.

Key Points: 
  • The FDA has assigned a Prescription Drug User Fee Act (PDUFA)goaldate of March 29, 2023, aligned with a Priority Review classification.
  • Furthermore, safety data from the study showed that leniolisib was well tolerated by participants.
  • Also submitted as part of the application were data from a long-term, open-label extension clinical trial including 38 patients with APDS who were treated with leniolisib for a median of 102 weeks.
  • Anurag Relan, MD, MPH, Chief Medical Officer of Pharming, commented:
    "The FDA's acceptance for priority review of Pharming's New Drug Application for leniolisib is a milestone that demonstrates our commitment to addressing unmet needs for patients with rare diseases.

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Retrieved on: 
Wednesday, September 28, 2022

LEIDEN, The Netherlands, Sept. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older in the US. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023, aligned with a Priority Review classification.

Key Points: 
  • The FDA has assigned a Prescription Drug User Fee Act (PDUFA)goaldate of March 29, 2023, aligned with a Priority Review classification.
  • Furthermore, safety data from the study showed that leniolisib was well tolerated by participants.
  • Also submitted as part of the application were data from a long-term, open-label extension clinical trial including 38 patients with APDS who were treated with leniolisib for a median of 102 weeks.
  • Anurag Relan, MD, MPH, Chief Medical Officer of Pharming, commented:
    "The FDA's acceptance for priority review of Pharming's New Drug Application for leniolisib is a milestone that demonstrates our commitment to addressing unmet needs for patients with rare diseases.

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing

Retrieved on: 
Wednesday, September 28, 2022

The Commitment Letter does not represent a definitive credit facility and is subject to certain conditions, including the consummation of a Gamida Cell equity offering resulting in gross proceeds of not less than $20 million.

Key Points: 
  • The Commitment Letter does not represent a definitive credit facility and is subject to certain conditions, including the consummation of a Gamida Cell equity offering resulting in gross proceeds of not less than $20 million.
  • Omidubicel is an advanced cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers.
  • For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn , Twitter , Facebook or Instagram at @GamidaCellTx.
  • Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell.

BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference

Retrieved on: 
Tuesday, September 27, 2022

Please contact your Roth representative to schedule one-on-one meetings with the management team during the conference.

Key Points: 
  • Please contact your Roth representative to schedule one-on-one meetings with the management team during the conference.
  • BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.
  • We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure.
  • The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.